Methodology

All entries for: Chronic Disease

April 24, 2024

BioMarin

Discontinued Drug, Discontinued Research, Layoffs

San Rafael, CA

1,001-5,000 employees

As a result of its prioritized portfolio, four programs will be discontinued, including BMN 331, BMN 255, BMN 355 and BMN 365. None of the programs were discontinued due to safety signals.

4 Discontinued Drugs: BMN 331 (biologic, orphan), BMN 255 (small molecule), BMN 355 (biologic), BMN 365 (biologic)
4 Discontinued Research Programs

Disease Area: Cardiology, Chronic Disease, Multiple, Rare Diseases

Drug Type: Biologic, Small Molecule

Source

August 2, 2022

Edgewise Therapeutics

Negative Outlook

Boulder, CO

51-200 employees

“The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates.”

Disease Area: Chronic Disease, Rare Diseases

Drug Type: Biologic, Small Molecule

Source